Brought to you by 
Altana's Byk Gulden and Genome Pharmaceuticals sign deal
13 Jul 1999
Executive Summary
Genome Pharmaceuticals Corp. (functional genomics) and Altana's subsidiary Byk Gulden (pharmaceuticals) will investigate new genomic targets to aid in the control of infections caused by the bacterial series H. pylori and Chlamydia pneumoniae.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Altana's Byk Gulden and Genome Pharmaceuticals sign deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice